BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition ...
Our study investigated microbial dynamics involved in the relative enrichment of oral bacteria in faeces. Results in mice and from human patients indicated that high percentages of oral bacteria ...